Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.
Yael Cohen, MD, vice president, Clinical Development, VBL Therapeutics, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.
Cohen says the treatment was initially tested in ovarian cancer as a dose escalation phase I trial across 3 cohorts of patients. She said in the phase I trial, researchers saw an overall response rate of about 60% in participating patients with platinum-resistant ovarian cancer.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More